

Letter to the Editor

SIR,

I read with interest the letter from Pedrazzini and colleagues [1], who feel that they can eliminate *cis*-platinum as a potential component of a synergistic action causing early-onset thrombocytopenia in the chemotherapy of testicular teratoma. I do not believe this to be a logical conclusion since the patients they describe received vinblastine and *cis*-platinum sequentially and not concurrently.

We mentioned in our article [2] that some of our patients had received vinblastine and *cis*-platinum on day 1 and bleomycin on day 2. Although the mean fall in the platelet count from day 1 to day 2 was not as marked in these patients as in the whole group, in six courses received by three patients there was a fall by day 2 of 30% or more.

G. J. G. REES
Bristol Radiotherapy and Oncology
Centre,
Horfield Road,
Bristol BS2 8ED, U.K.

REFERENCES

1. Pedrazzini A, Cavalli F, Kiser J, Goldhirsch A. Early-onset thrombocytopenia in the chemotherapy of testicular teratoma. *Eur J Cancer Clin Oncol* 1983, **19**, 867.
2. Rees G JG, Slade RR, Hopes P. Reduced platelet survival following chemotherapy with vinblastine, bleomycin and *cis*-platinum for testicular teratoma. *Eur J Cancer Clin Oncol* 1982, **18**, 1125-1129.